News stories about Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) have been trending positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Tetralogic Pharmaceuticals Corp earned a news sentiment score of 0.37 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.0098148323858 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) traded down 3.1250% during mid-day trading on Tuesday, reaching $0.0155. The company’s stock had a trading volume of 1,000 shares. The firm’s market capitalization is $383919.50. Tetralogic Pharmaceuticals Corp has a 12 month low of $0.02 and a 12 month high of $0.25. The stock’s 50-day moving average is $0.02 and its 200-day moving average is $0.04.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at

About Tetralogic Pharmaceuticals Corp

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.

Insider Buying and Selling by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)

Receive News & Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.